| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	-SEC Filing
 
																	JMP Securities analyst Jonathan Wolleben upgrades Spruce Biosciences (NASDAQ:SPRB) from Market Perform to Market Outperform ...
 
																	-SEC Filing
 
																	Spruce Biosciences, Inc. (NASDAQ:SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel ...
 
																	
 
																	
 
																	 
																	
